Agenus AGEN
NASDAQ AGEN
$8.22 -0.02 (-0.24%)
As of: Sep 4, 2026 · 2:41 PM EDT

Agenus (AGEN) Net Income towards Common Stockholders (2010 - 2026)

Agenus (AGEN) posted quarterly Net Income towards Common Stockholders of $39.2 million for Q1 2026, up 254.71% year-over-year from $11.0 million in Q1 2025, and up 468.43% quarter-over-quarter from -$10.6 million in Q4 2025.

Analysis

Agenus (AGEN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Agenus' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $39.2 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders rose 254.71% year-over-year to $39.2 million; the TTM figure through Mar 2026 stood at $64.4 million (up 133.75% YoY), while the FY2025 annual figure was -$101000.0, up 99.96% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at $39.2 million, up from -$10.6 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $63.9 million in Q3 2025, with the low at -$71.1 million in Q4 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$48.4 million (2022), against an average of -$38.5 million.
  • The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders slumped 130.41% in 2022, then surged 254.71% in 2026.
  • Agenus' Net Income towards Common Stockholders stood at -$71.1 million in 2022, then jumped by 34.86% to -$46.3 million in 2023, then climbed by 0.93% to -$45.9 million in 2024, then jumped by 76.84% to -$10.6 million in 2025, then surged by 468.43% to $39.2 million in 2026.
  • Business Quant data shows AGEN's Net Income towards Common Stockholders at $39.2 million in Q1 2026, -$10.6 million in Q4 2025, and $63.9 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn - -644.37 Mn
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn - 81.49 Mn
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn -13.27 Mn
10 Agenus 339.80 Mn 339.80 Mn 34.52 Mn -604,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -604,000.00
Mar 31, 2026 39.17 Mn
Dec 31, 2025 -10.63 Mn
Sep 30, 2025 63.86 Mn
Jun 30, 2025 -28.01 Mn
Mar 31, 2025 -25.32 Mn
Dec 31, 2024 -45.91 Mn
Sep 30, 2024 -66.44 Mn
Jun 30, 2024 -53.14 Mn
Mar 31, 2024 -61.94 Mn
Dec 31, 2023 -46.34 Mn
Sep 30, 2023 -62.25 Mn
Jun 30, 2023 -69.07 Mn
Mar 31, 2023 -68.31 Mn
Dec 31, 2022 -71.15 Mn
Sep 30, 2022 -54.28 Mn
Jun 30, 2022 -46.49 Mn
Mar 31, 2022 -48.38 Mn
Dec 31, 2021 -65.56 Mn
Sep 30, 2021 178.50 Mn